In this study, we want to understand your health status and how well your inoperable and/or metastatic HER2-low breast cancer can be controlled with Enhertu® or the treatment of your choice by your doctor. In addition, we would like to investigate how the drug Enhertu® compares with conventional chemotherapy in clinical practice.
Aim of the study
The purpose of this study is to collect information about your health status, how well you tolerate your cancer treatment prescribed by your doctor and how it is used in routine clinical practice in patients with inoperable and/or metastatic HER2-low breast cancer. In addition, we would like to investigate how the drug Enhertu® compares with conventional chemotherapy in clinical practice
Who can take part?
Patients with inoperable and/or metastatic HER2-low breast cancer
Procedure
You will be asked to complete 2 questionnaires at the baseline data collection point, then every cycle until 6 months after starting treatment with Enhertu® or conventional chemotherapy, and then every three months until the end of your initial treatment. After completing your initial treatment, you will be asked to complete the questionnaires every 6 months until you finish the study and once a month.
End of the study.
Compensation
none
Original study name
A prospective, non-interventional study (NIS) of trastuzumab deruxtecan for patients with unresectable and/or metastatic HER2-low breast cancer, accompanied by a disease registry of patients treated with conventional chemotherapy.
BASEC number
2023-02029
Sponsors